Treatment of Primary Tumors and Tumor Metastases with TNF-alpha Antagonists


The role of TGF-beta1 in tumorigenesis is well-documented. However, the mechanism behind the induction of TGF-beta1 remains poorly understood. As a result, potential targets for the treatment of cancers associated with TGF-beta1 have escaped detection. This invention uncovers a two-step process of TGF-beta1 induction, thereby providing alternative targets for cancer treatment.

TGF-beta1 induction requires signaling through by IL-13 through IL13-Ralpha2. However, IL13-Ralpha2 must first be induced, requiring signaling by TNFalpha and IL4 or IL-13 through IL13-Ralpha1. Thus, by blocking TNFalpha signaling, one can block the expression of TGF-beta1. This invention concerns new methods of treating cancers associated with TGF-beta1 expression involving the administration of TNFalpha antagonists.

Potential Commercial Applications: Competitive Advantages:
New cancer treatment for a wide variety of cancers, including colon cancer. Provides a treatment option for patients who don’t respond to currently available anti-cancer agents.


Inventors:

Warren Strober (NIAID)  ➽ more inventions...


Intellectual Property:
PCT Pat: - issued -
US Application No. 60/962,668 filed on 2007-07-31
US Application No. 12/671,652 filed on 2010-02-01

Collaboration Opportunity:

The National Institutes of Health, NIAID, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize “Treatment of Primary Tumors and Tumor Metastases with TNF-alpha Antagonists.” Please contact Dr. Warren Strober at WStrober@niaid.nih.gov for more information.


Licensing Contact:
Charles Rainwater,
Email: crainwater@niaid.nih.gov
Phone: 301-496-2644

OTT Reference No: E-161-2007-0
Updated: Sep 1, 2007